

Table 1. Patient Characteristics

---

Characteristics	
<i>Sex (number of patients)</i>	
Male	12
Female	19
<i>Age (yrs)</i>	
Mean $\pm$ SD	64.8 $\pm$ 8.0
Range	43-77
<i>Duration of disease (yrs)</i>	
Mean $\pm$ SD	11.3 $\pm$ 5.5
Range	3-29
<i>PreOP. medications (mg/day)</i>	
<i>Levodopa and DCI</i>	
Mean $\pm$ SD	419.4 $\pm$ 137.7
Range	150-650
<i>LEDD (mg)</i>	
Mean $\pm$ SD	494.8 $\pm$ 188.5
Range	150.0-849.8

---

Table 2. Effects of STN stimulation

		Baseline	3 months
UPDRS I	ON	1.8 ± 2.1	1.1 ± 1.5*
	OFF	2.5 ± 2.4	1.1 ± 1.5*
UPDRS II	ON	13.7 ± 10.9	7.4 ± 8.3*
	OFF	24.3 ± 10.9	9.7 ± 8.1*
UPDRS III	ON	26.4 ± 19.7	13.7 ± 13.1*
	OFF	44.9 ± 16.3	16.7 ± 13.3*
Bradykinesia	ON	9.6 ± 7.4	5.4 ± 5.4*
	OFF	15.9 ± 6.6	6.3 ± 5.6*
Tremor	ON	2.4 ± 3.1	1.3 ± 2.0*
	OFF	5.3 ± 5.5	1.9 ± 3.0*
Rigidity	ON	4.7 ± 5.4	1.0 ± 2.4*
	OFF	7.2 ± 5.3	1.2 ± 2.6*
Axial symptoms	ON	9.1 ± 7.2	5.5 ± 6.3*
	OFF	17.9 ± 7.1	6.7 ± 6.3*
UPDRS IV		6.2 ± 3.3	2.7 ± 1.8*
S-E ADL scale	ON	72.6 ± 17.1	80.0 ± 15.9*
	OFF	50.7 ± 15.3	75.8 ± 15.9*
Levodopa/DCI (mg)		419.4 ± 137.7	324.2 ± 119.0 <sup>#</sup>
LEDD (mg)		494.8 ± 188.5	353.7 ± 129.5 <sup>#</sup>

Asterix: significantly different from scores at preoperative baseline, \*p<0.001, Wilcoxon signed-rank test, and <sup>#</sup>p<0.001, Student's t-test